Table 3.
Safety outcomes of patients with type 2 diabetes and diabetic retinopathy showing no significant risk in both groups.
| DDP4i | Non-DDP4i | DPP4i vs. Non-DPP4i | ||
|---|---|---|---|---|
| Outcome | (n = 20,444) | (n = 20,444) | SHR (95% CI) | p-Value |
| Myocardial infarction | 252 (1.2) | 268 (1.3) | 0.93 (0.78–1.10) | 0.396 |
| Hospitalization for heart failure | 495 (2.4) | 441 (2.2) | 1.11 (0.98–1.26) | 0.115 |
| Ischemic stroke | 872 (4.3) | 839 (4.1) | 1.02 (0.93–1.13) | 0.621 |
| Hemorrhagic stroke | 131 (0.64) | 151 (0.74) | 0.85 (0.68–1.08) | 0.183 |
| Major adverse cardiovascular events * | 1600 (7.8) | 1529 (7.5) | 1.05 (0.98–1.12) | 0.198 |
DDP4i, dipeptidyl peptidase 4 inhibitor; SHR, sub-distribution hazard ratio; CI, confidence interval. * Any one of myocardial infarction, heart failure, or stroke.